Methotrexate and not much harm to the lungs

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages 10-

  Yazici, Hasan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT;

COMORBIDITY; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; HUMAN; LETTER; LUNG DISEASE; MEDICAL PRACTICE; MEDICAL RECORD; META ANALYSIS (TOPIC); PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; LUNG DISEASES; METHOTREXATE;

EID: 84922523771     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. CONWAY R, LOW C, COUGHLAN RJ, O'DONNELL MJ, CAREY CC: Methotrexate and lung disease in rheumatoid arthritis. A meta-analysis of randomized controlled trials. Arthritis Rheum 2014; 66: 803-12.
2. PINCUS T: Limitations of traditional randomized controlled clinical trials in rheumatology. In: Understanding Evidence Based Rheumatology. YAZICI H, YAZICI Y, LESAFFRE E (Eds.) Springer, New York (in press).